Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa)

被引:64
作者
Cardillo, Giuseppe [1 ]
Carleo, Francesco [1 ]
Giunti, Roberto [1 ]
Lopergolo, Michele Giovanni [1 ]
Salvadori, Lorenzo [1 ]
De Massimi, Alessia Raffaella [1 ]
Petrella, Lea [2 ]
Martelli, Massimo [1 ]
机构
[1] Azienda Osped San Camillo Forlanini, Unit Thorac Surg, Carlo Forlanini Hosp, I-00149 Rome, Italy
[2] Univ Roma La Sapienza, Dept Studi Geoecon, Rome, Italy
关键词
Thymoma; Thymic carcinoma; Induction therapy; Surgery; INVASIVE THYMOMA; NEOADJUVANT CHEMOTHERAPY; SURGICAL RESECTION; EPITHELIAL TUMORS; RADIATION-THERAPY; FOLLOW-UP; CLASSIFICATION;
D O I
10.1016/j.ejcts.2009.11.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to evaluate factors influencing long-term survival of patients with locally advanced thymoma/thymic carcinoma (Masaoka stages III and IVa) treated by immediate surgery or induction therapy plus surgery. Methods: From January 1991 to April 2007, we surgically treated 61 patients with locally advanced thymoma/thymic carcinoma (Masaoka stages Ill and IVa). Staging included total body computed tomography (CT) scan in all patients, and chest magnetic resonance imaging (MRI) in 27 selected patients. All patients had histological confirmation before surgery. Thirty-one patients (group A) underwent induction chemotherapy followed by surgery. Thirty patients (group B) underwent immediate surgery. Thirty-four patients (group A: 13; group B: 17) received postoperative radiation therapy. Results: No intra-operative mortality was reported. World Health Organization (WHO) histological classification included 19 AB, four B1, seven B2 and 13 B3 thymomas and 18 thymic carcinomas. Thirty-four patients were Masaoka stage III (group A: 18; group B: 16) and 27 patients were stage IVa (group A: 13; group B: 14). After a median follow-up of 77 months, six patients of group A and seven patients of group B died of disease. The overall 10-year survival rate was 50.6%. The 10-year survival rate was 57.9% in group A and 38.1% in group B (p = 0.03). Multivariate analysis showed complete resection (p = 0.02), Masaoka stage (III vs IVa) (p = 0.02), induction chemotherapy (group A vs group B) (p = 0.003) and histological WHO subtype (AB vs B1, 82 and B3) (p = 0.01) to be statistically significant independent predictors of survival. Sex, age and adjuvant radiation therapy showed no statistically significant difference. Conclusions: Complete resection, Masaoka stage, induction chemotherapy and histological WHO classification showed to be independent predictors of survival in locally advanced thymoma/thymic carcinoma. (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:819 / 823
页数:5
相关论文
共 26 条
[1]   THYMOMA - A MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING SURVIVAL [J].
BLUMBERG, D ;
PORT, JL ;
WEKSLER, B ;
DELGADO, R ;
ROSAI, J ;
BAINS, MS ;
GINSBERG, RJ ;
MARTINI, N ;
MCCORMACK, PM ;
RUSCH, V ;
BURT, ME .
ANNALS OF THORACIC SURGERY, 1995, 60 (04) :908-914
[2]   INVASIVE THYMOMA - THE ROLE OF MEDIASTINAL IRRADIATION FOLLOWING COMPLETE OR INCOMPLETE SURGICAL RESECTION [J].
CURRAN, WJ ;
KORNSTEIN, MJ ;
BROOKS, JJ ;
TURRISI, AT .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (11) :1722-1727
[3]   Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors [J].
Endo, Masahiro ;
Nakagawa, Kazuo ;
Ohde, Yasuhisa ;
Okumura, Takehiro ;
Kondo, Haruhiko ;
Igawa, Satoshi ;
Nakamura, Yukiko ;
Tsuya, Asuka ;
Murakami, Haruyasu ;
Takahashi, Toshiaki ;
Yamamoto, Nobuyuki ;
Ito, Ichiro ;
Kameya, Toru .
LUNG CANCER, 2008, 61 (03) :350-355
[4]  
GIACCONE G, 1985, CANCER TREAT REP, V69, P695
[5]   Feasibility of multimodality therapy including extended resections in stage IVA thymoma [J].
Huang, James ;
Rizk, Nabil P. ;
Travis, William D. ;
Seshan, Venkatraman E. ;
Bains, Manjit S. ;
Dycoco, Joseph ;
Downey, Robert J. ;
Flores, Raja M. ;
Park, Bernard J. ;
Rusch, Valerie W. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 134 (06) :1477-1484
[6]   Thymoma: Update for the new millenium [J].
Johnson, SB ;
Eng, TY ;
Giaccone, G ;
Thomas, CR .
ONCOLOGIST, 2001, 6 (03) :239-246
[7]   Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report [J].
Kim, ES ;
Putnam, JB ;
Komaki, R ;
Walsh, GL ;
Ro, JY ;
Shin, HJ ;
Truong, M ;
Moon, H ;
Swisher, SG ;
Fossella, FV ;
Khuri, FR ;
Hong, WK ;
Shin, DM .
LUNG CANCER, 2004, 44 (03) :369-379
[8]   Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors [J].
Lardinois, D ;
Rechsteiner, R ;
Läng, H ;
Gugger, M ;
Betticher, D ;
von Briel, C ;
Krueger, T ;
Ris, HB .
ANNALS OF THORACIC SURGERY, 2000, 69 (05) :1550-1555
[9]   Neoadjuvant chemotherapy for stage III and IVA thymomas: A single-institution experience with a long follow-up [J].
Lucchi, Marco ;
Melfi, Franca ;
Dini, Paolo ;
Basolo, Fulvio ;
Viti, Andrea ;
Givigliano, Francesco ;
Angeletti, Carlo Alberto ;
Mussi, Alfredo .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (04) :308-313
[10]  
MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO